Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus DIFLUNISAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus DIFLUNISAL.
BUTAZOLIDIN vs DIFLUNISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
None Documented
None Documented
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Category C
Category C
NSAID
NSAID